Caribou Biosciences【CRBU】銘柄情報

Caribou Biosciences Inc (CRBU) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

1.9592

( 0.99% )

買値

1.74

売値

1.96

出来高

3,477,088

平均取引量 (3 か月)

US$ 1,917,345

財務取引量

US$ 6,339,467

1.755 日の範囲 1.935

1.39 52 週間の範囲 3.52

時価総額

194.315M

企業価値

89.819M

前日終値

1.94

始値

1.935

時刻

1000

1.9592

(formt)

最終取引時間

VWAP

1.8232

歳入

11.2M

純利益

-133.22M

発行済株式数

99,180,575

浮動株比率 (%)

95.59%

機関投資家保有比率 (%)

40.41%

配当利回り

PER

-1.29

株価売上高倍率 (PSR)

16.2

1 株当たり利益 (EPS)

-1.41

ベータ

2.36

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing o... Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California. 詳細を表示

セクター

Health Care

業界

ウェブサイト

cariboubio.com

本社

Berkeley, United States

設立

2026

Caribou Biosciences Inc is listed in the Health Care sector of the ナスダック市場 with ticker CRBU. The last closing price for Caribou Biosciences was US$1.94. Over the last year, Caribou Biosciences shares have traded in a share price range of US$ 1.39 to US$ 3.52.

Caribou Biosciences currently has 99,180,575 shares in issue. The market capitalisation of Caribou Biosciences is US$194.31 million. Caribou Biosciences has a price to earnings ratio (PE ratio) of -1.29.

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading...

Form 8-K - Current report

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a...

Form 8-K - Current report

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and...

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r...

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.1292	7.06010928962	1.83	2.11	1.75	2389462	1.92251911	CS
4	0.2192	12.5977011494	1.74	2.11	1.56	2707387	1.72854201	CS
12	-0.2608	-11.7477477477	2.22	2.49	1.56	2026870	1.93362995	CS
26	0.3192	19.4634146341	1.64	2.49	1.39	1617151	1.8768168	CS
52	0.1592	8.84444444444	1.8	3.52	1.39	1662352	2.02657094	CS
156	-5.5008	-73.7372654155	7.46	8.5899	0.66	1633470	3.03448538	CS
260	-15.6908	-88.8997167139	17.65	32.645	0.66	1325530	4.80173673	CS

CRBU - Frequently Asked Questions (FAQ)

What is the current Caribou Biosciences Inc share price?

The current share price of Caribou Biosciences Inc is US$ 1.9592

How many Caribou Biosciences Inc shares are in issue?

Caribou Biosciences Inc has 99,180,575 shares in issue

What is the market cap of Caribou Biosciences Inc?

The market capitalisation of Caribou Biosciences Inc is USD 194.31M

What is the 1 year trading range for Caribou Biosciences Inc share price?

Caribou Biosciences Inc has traded in the range of US$ 1.39 to US$ 3.52 during the past year

What is the PE ratio of Caribou Biosciences Inc?

The price to earnings ratio of Caribou Biosciences Inc is -1.29

What is the cash to sales ratio of Caribou Biosciences Inc?

The cash to sales ratio of Caribou Biosciences Inc is 16.2

What is the registered address of Caribou Biosciences Inc?

The registered address for Caribou Biosciences Inc is 2929 7th Street, Berkeley, California, 94710

What is the Caribou Biosciences Inc website address?

The website address for Caribou Biosciences Inc is cariboubio.com

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Caribou Biosciences Inc (CRBU)

Caribou Biosciences Inc (CRBU) 銘柄情報

個人投資家向けのプロ仕様のツール。

主要統計と詳細

Caribou Biosciences Inc について

CRBU 最新ニュース

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Form 8-K - Current report

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Form 8-K - Current report

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Form 8-K - Current report

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Form 8-K - Current report

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Form 8-K - Current report

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

CRBU - Frequently Asked Questions (FAQ)

CRBU 取引

CRBU Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する